Mineralys Therapeutics, Inc. $MLYS Stock Sold by CenterBook Partners LP

Mineralys Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CenterBook Partners cut its Mineralys Therapeutics stake by 64.5% in the third quarter, selling 235,710 shares and retaining 129,920 shares valued at about $3.27 million.
  • Mineralys reported a quarterly loss of $0.64 per share, missing analyst expectations of a $0.55 loss. The stock opened at $15.33, near its 52-week low of $14.91.
  • Analysts’ consensus rating is Hold, with an average price target of $45.50; institutional investors collectively own 84.46% of the company.
  • Five stocks we like better than Mineralys Therapeutics.

CenterBook Partners LP lessened its holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 64.5% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 129,920 shares of the company's stock after selling 235,710 shares during the period. CenterBook Partners LP owned 0.15% of Mineralys Therapeutics worth $3,265,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of Mineralys Therapeutics in the 2nd quarter valued at about $158,832,000. Orbimed Advisors LLC increased its position in shares of Mineralys Therapeutics by 109.4% in the first quarter. Orbimed Advisors LLC now owns 2,052,900 shares of the company's stock worth $55,613,000 after purchasing an additional 1,072,500 shares during the last quarter. Bank of America Corp DE purchased a new stake in Mineralys Therapeutics in the second quarter valued at approximately $40,620,000. Jennison Associates LLC raised its stake in Mineralys Therapeutics by 0.6% in the first quarter. Jennison Associates LLC now owns 1,266,174 shares of the company's stock valued at $34,301,000 after purchasing an additional 7,521 shares in the last quarter. Finally, Nantahala Capital Management LLC purchased a new stake in Mineralys Therapeutics in the second quarter valued at approximately $22,136,577. Institutional investors own 84.46% of the company's stock.

Mineralys Therapeutics Price Performance

MLYS stock opened at $15.33 on Friday. The firm has a market cap of $1.36 billion, a P/E ratio of -3.52 and a beta of 0.83. The firm's fifty day moving average is $23.78 and its 200 day moving average is $26.61. Mineralys Therapeutics, Inc. has a 52 week low of $14.91 and a 52 week high of $47.65. The company has a debt-to-equity ratio of 0.18, a quick ratio of 34.46 and a current ratio of 34.46.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.09). Research analysts predict that Mineralys Therapeutics, Inc. will post -4.60 earnings per share for the current year.

Insider Activity

In other news, insider Eric Warren sold 7,438 shares of the business's stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $28.12, for a total value of $209,156.56. Following the completion of the sale, the insider owned 38,400 shares of the company's stock, valued at approximately $1,079,808. The trade was a 16.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daphne Karydas sold 3,000 shares of the stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $28.58, for a total value of $85,740.00. Following the sale, the director owned 6,200 shares of the company's stock, valued at $177,196. This represents a 32.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 199,365 shares of company stock valued at $5,461,854. Company insiders own 18.94% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on MLYS shares. Zacks Research upgraded shares of Mineralys Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Friday, September 11th. Wall Street Zen lowered shares of Mineralys Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, August 15th. Weiss Ratings restated a "sell (d-)" rating on shares of Mineralys Therapeutics in a research report on Thursday, October 15th. HC Wainwright restated a "buy" rating and set a $56.00 price objective on shares of Mineralys Therapeutics in a research report on Monday, October 12th. Finally, UBS Group initiated coverage on shares of Mineralys Therapeutics in a report on Sunday, October 11th. They set a "neutral" rating and a $29.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $45.50.

Check Out Our Latest Report on MLYS

About Mineralys Therapeutics

(Free Report)

Mineralys Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and kidney diseases associated with excess aldosterone activity. The company's research centers on selectively targeting aldosterone production, a mechanism involved in blood-pressure regulation and organ damage.

Mineralys' lead product candidate is lorundrostat, an oral, selective aldosterone synthase inhibitor being evaluated as a potential treatment for uncontrolled and resistant hypertension.

Featured Articles

Want to see what other hedge funds are holding MLYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report).

Institutional Ownership by Quarter for Mineralys Therapeutics (NASDAQ:MLYS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Mineralys Therapeutics Right Now?

Before you consider Mineralys Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mineralys Therapeutics wasn't on the list.

While Mineralys Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines